Center news
RADx Tech COVID-19 Funding Opportunity: COVID-19 Home Tests Accessible to People with Disabilities
The RADx Coordination Center at CIMIT, on behalf of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the National Institutes of Health (NIH), is soliciting proposals for accessible over-the-counter (OTC) testing technologies for COVID-19 under its Rapid Acceleration of Diagnostics (RADx) fast-track program.
Under this RADx Tech solicitation, NIBIB is seeking to accelerate the development of OTC COVID-19 diagnostic technologies that can be used independently by people with disabilities. To specifically meet the needs of populations with disabilities (e.g., blindness, low vision, fine motor skill difficulties, and aging-related disabilities) innovations should incorporate universal design features and provide significantly improved accessibility and ease-of-use compared to existing commercial platforms. Proposals should utilize universal design principles such that solutions will improve the usability of OTC tests for all users. Clinical and technical performance must be at least as good as current, best-in-class OTC technologies. Test platforms should return results quickly, demonstrate potential for integration with digital health reporting standards, and be capable of achieving regulatory clearance during both pandemic and non-pandemic periods.
The RADx Coordination Center at CIMIT, on behalf of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the National Institutes of Health (NIH), is soliciting proposals for accessible over-the-counter (OTC) testing technologies for COVID-19 under its Rapid Acceleration of Diagnostics (RADx) fast-track program.
Under this RADx Tech solicitation, NIBIB is seeking to accelerate the development of OTC COVID-19 diagnostic technologies that can be used independently by people with disabilities. To specifically meet the needs of populations with disabilities (e.g., blindness, low vision, fine motor skill difficulties, and aging-related disabilities) innovations should incorporate universal design features and provide significantly improved accessibility and ease-of-use compared to existing commercial platforms. Proposals should utilize universal design principles such that solutions will improve the usability of OTC tests for all users. Clinical and technical performance must be at least as good as current, best-in-class OTC technologies. Test platforms should return results quickly, demonstrate potential for integration with digital health reporting standards, and be capable of achieving regulatory clearance during both pandemic and non-pandemic periods.